Skip to main content

What the FDA labels say about taking them together

Anagrelide and disopyramide

Anagrelide's FDA label of April 8, 2026 names disopyramide in its drug interactions section; the disopyramide label PlainMeds reads does not name anagrelide. The anagrelide label: “Drugs that Prolong QT Avoid use of AGRYLIN in patients taking medications that may prolong QT interval.”

Check it at the source: the anagrelide FDA label on DailyMed (effective April 8, 2026, Takeda Pharmaceuticals America, Inc.); the disopyramide FDA label on DailyMed (effective August 24, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the anagrelide label say about disopyramide?

Anagrelide label, drug interactions

Drugs that Prolong QT Avoid use of AGRYLIN in patients taking medications that may prolong QT interval (including, but not limited to, chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin, amiodarone, disopyramide, procainamide, and pimozide) [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2) ].

Source: FDA drug label (Agrylin), Takeda Pharmaceuticals America, Inc., effective April 8, 2026 (SPL set cb960074-99c1-4a73-941f-f0644a7ec219), via openFDA; the full label on DailyMed

What does the disopyramide label say about anagrelide?

Disopyramide's label (effective August 24, 2026) does not name anagrelide in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Norpace), Pfizer Laboratories Div Pfizer Inc, effective August 24, 2026 (SPL set e2aa1642-d262-4520-bc6a-9fd3ad795677), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

3Anagrelide generic labelers
2Disopyramide generic labelers
AnagrelideDisopyramide
Labeled forn/an/a
Boxed warningNoYes
Pharmacy cost (NADAC)$0.729 per capsule 0.5 mg capsule$0.801 per capsule 100 mg capsule
Shortage nowA presentation being discontinuedA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?